SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

SNDL Inc.NASDAQ: SNDL

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables rises 7.2% from a year ago

Net receivables stood at CA$31.91M at the end of Q1 FY2026, up 7.2% from a year earlier and up 4.8% from the prior quarter. Over 3 fiscal years it compounded at +10.4% a year.

Context

  • Net receivables amounted to 2.4% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
  • Net receivables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +7.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$31.91M+4.8% QoQ
Last fiscal yearDec 2025
CA$30.45M+8.3% YoY
Year agoMar 2025
CA$29.78M+7.2% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.2%——
1 year+8.3%——
3-year CAGR+10.4%——
5-year CAGR——
10-year CAGR——

Net Receivables history

CAD · from the balance sheet

Latest · FY2025
30.45M CAD
Year-over-year change
+8.3%
4-year CAGR
+29.4%

Net Receivables vs competitors

How SNDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +7.2% is the 6th highest of 11, against a peer median of +5.8%.
  • Net receivables amounts to 2.4% of total assets for SNDL, versus a peer median of 7.0%.
SNDL Competitors
Net Receivables for SNDL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ESPREsperion Therapeutics, Inc.Mar 2026$132.35M USD+62.8%+60.8%28.6%
EBSEmergent BioSolutions Inc.Mar 2026$121.6M USD-40.3%-19.1%9.2%
ORGOOrganogenesis Holdings Inc.Mar 2026$116.91M USD+13.2%+34.5%22.5%
AKBAAkebia Therapeutics, Inc.Mar 2026$62.54M USD+1.6%+5.3%17.3%
EOLSEvolus, Inc.Mar 2026$52.22M USD+10.0%+34.6%23.7%
SNDLSNDL Inc.Mar 2026CA$31.91M CAD+7.2%+10.4%2.4%
CMPSCOMPASS Pathways plcMar 2026$15.13M USD-51.7%-0.5%2.8%
AQSTAquestive Therapeutics, Inc.Mar 2026$6.87M USD-34.2%+55.7%4.9%
SIGASIGA Technologies, Inc.Mar 2026$4.5M USD-37.4%-58.4%2.1%
OLMAOlema Pharmaceuticals, Inc.Mar 2026$3.35M USD+74.5%+133.4%0.6%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$1.2M USD+427.8%-16.1%0.5%
Peer median (excluding SNDL) —+5.8%+19.9%7.0%

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents558.25M279.59M195.04M218.36M272.6M
Short-term Investments90.78M32.18M6.6M30.53M568.57K
Net Receivables10.87M22.64M27.06M28.12M30.45M
Inventory33.91M131.26M129.49M129.11M130.13M
Other Current Assets30.01M25.71M26.27M38.87M16.33M
Total Current Assets728.18M501.48M406.91M461.84M450.07M
Property, Plant & Equipment (Net)63.19M277.56M282.6M261.25M290.55M
Goodwill72.5M67.26M119.28M124.25M124.37M
Intangible Assets50.15M74.89M73.15M61.33M58.58M
Long-term Investments505.93M629.58M586.39M436.91M409.16M
Tax Assets00000
Other Non-current Assets7.73M8.58M4.84M3.68M4.53M
Total Non-current Assets699.49M1.06B1.07B887.4M887.19M
Total Assets1.43B1.56B1.47B1.35B1.34B
Account Payables4.17M9.77M22.04M27.06M28.03M
Short-term Debt000035.5M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities21.7M11M4.4M26K28.77M
Total Current Liabilities65.85M89.36M103.15M90.56M92.3M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities4.51M2.71M4.19M7.31M8.05M
Total Non-current Liabilities32.27M142.33M140.68M125.33M142.66M
Total Liabilities98.13M231.7M243.82M215.89M234.96M
Common Stock2.04B2.29B2.38B2.35B2.31B
Retained Earnings(785.11M)(1.09B)(1.26B)(1.32B)(1.3B)
Accumulated OCI7.61M32.19M19.42M52.77M39.24M
Other Stockholders Equity10.37M4.54M4.54M667K0
Minority Interest229K21.16M17.27M00
Total Equity1.33B1.33B1.23B1.13B1.1B
Total Debt33.47M169.83M167.03M152.27M170.1M
Net Debt(524.78M)(109.76M)(28.01M)(66.09M)(102.49M)

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.